Lobbyist information

Amount

Carol J. Holahan	$76,000.00
Employed Terminated 01/01/2020

Dean Richlin	$0.00
Employed Terminated 01/01/2020

Pat A. Cerundolo	$145,011.00
Employed Terminated 01/01/2020

Total salaries paid:      $221,011.00

Client information

Amount

American Chemistry Council	$50,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2020 Areas of Interest: All matters associated with chemical and product bans as well as environmental regulations. Names of Legislators/ Regulatory Bodies: TURI and associated boards (Science Advisory Board, Administrative Council), Executive Office of Energy and Environmental Affairs, MassDEP

Amgen, Inc.	$0.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2020 Legislation, regulations, and issues related to biopharmaceuticals, health care, and economic development.

bluebird bio	$25,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/15/2020 State Medicaid coverage and payment policies for gene therapies

BROOKFIELD POWER US ASSET MANAGEMENT LLC

$36,000.00

Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2020 Areas pertaining to clean energy legislation in the Commonwealth, including potential bills on clean energy and the state Renewable Portfolio Standard, energy storage and climate change. Members, Senate and House Chairs of the Telecommunications and Energy Committee and Energy and Environmental Affairs staff members. As well as Office of Energy and Environmental Affairs (and associated sub-departments).

Gilead Sciences, Inc.	$0.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2020 Any and all matters relating to Gilead Sciences, Inc. including HIV/AIDS, Hepatitis C, drug pricing policy, and patient access to health care.

Massachusetts Biotechnology Council

$120,011.00

Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2020 Any and all legislation and regulations pertaining to the healthcare system; Any issue that impacts a biopharmaceutical company's ability to market or sell its products in all sectors and markets in the Commonwealth; any policy or proposal that seeks to limit or restrict unfettered patient access to innovative medicines and therapies in the Commonwealth; implementation of Chapter 224 the Acts of 2012, health care reform, drug innovation, pharmaceuticals, recycling and disposal policies, provider

Vertex Pharmaceuticals, Incorporated	$0.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2020 All matter related to Patient access to medicines, medicaid, drug pricing, and drug coast containment.

Total salaries received:      $231,011.00

Expenditures

Amount